

Closed Systems in CNC Ballroom

A Risk Based Approach

#sharing challenges and solutions in practice

Part of PharmaCongress – Düsseldorf/Neuss, 31 May–1 June 2022











Lars Hovmand-Lyster



- Senior Engineering specialist in Novo Nordisk Investment Project Office (IPO)
- Biophorum (formerly BPOG) Closed Systems in CNC workstream
- Process Closure Playbook 2022 (BioPhorum)
- Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations (PDA journal 2021)
- Quality Risk Management facilitator for Product protection/Closed Systems
- More than 20 of year experience with QC, Upstream/ downstream processes and process engineering
- Based in Bagsvaerd, Denmark







Who is Biophorum?

- Cross industry collaboration with the aim of:
- Accelerating the rate at which the biopharma industry attains a mature and lean state, benefitting patients and stakeholders alike.
 - Best practice sharing
 - Benchmarking
 - Joint-solution development to common challenges
 - Definition of standard requirements
 - Formation of collective perspectives to regulatory guidelines.



Supported by





Training, Conferences, Services



© ECA Academy – www.gmp-compliance.org

Membership includes most of the top biopharma manufacturers

PHARMA

CONGRESS



© ECA Academy – www.gmp-compliance.org

eca

Pharmaceutical Quality

Training, Conferences, Services,

YOUR GMP/GDP

Information Source

...and many of the key industry supply partners



Correct as at 18.03.22

Academy ECA * YOUR GMP/GDP Information Source

© ECA Academy – www.gmp-compliance.org © BioPhorum Operations Group Ltd



Supported by CONCEPT HEIDELBERG Pharmaceutical Quality

Training, Conferences, Services,

5

Agenda

- Regulatory guidance
- Understanding closure
- **Risk Assessment**
- Facility impact
- Conclusion







raining, Conferences, Services





Slide 6

Regulatory guidance encourage utilizing closed systems



FDA U.S. FOOD & DRUG



PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME

> PE 009-13 (Part II) 1 January 2017

- 4 Buildings and Facilities
- 4.1 Design and Construction
- 4.10 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance, and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.
- 4.11 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.
- 4.12 Where the equipment itself (e.g., closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.

4.12 Where the equipment itself (e.g., closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.







monisation for better health

Understanding closure

- ISPE definitions
 - Closed system (equipment)
 - Functionally closed (equipment)
 - Briefly exposed process
 - Open process







Pharmaceutical Quality Training. Conferences. Service

Method of closure

Something we do before operating the system


Closed

Not exposed to the production environment E. g. Pre sterilized single us e bioreactor






Functionally closed Exposed to the production environment and then closed by







BPOG study in cooperation with BTEC

Functionally closed by CIP using industry solvents Opened temporarily to connect Functionally closed using WFI or industry solvents

BTEC = Biomanufacturing Training and Education Center





Training, Conferences, Services



© ECA Academy – www.gmp-compliance.org

Operation of system

Operated Closed Both Closed SUS and functionally closed

Protected from the production environment at all time. Room classification not required


Briefly exposed process


y Product exposed to the Production environment followed by mitigation. Room classification maybe not required

Open process

Product exposed to production environment must be protected by appropriate room classification














raining, Conferences, Services

Supported by



Potential Sources of Contamination








Training, Conferences, Services,

Supported by



Operational Philosophy









Pharmaceutical Quality Training. Conferences. Services.

Supported by

Closed Single-Use System for <u>Aseptic Process</u> (e.g. cell culture)

Components and Equipment

- Integral
- Sterile

System Assembly


- Performed aseptically
- Never expose product contact surfaces

All Additions

- Sterile
- Goal is axenic inoculum & production culture

Integrity of System

Maintained until clearance of product





Functionally Closed Single-Use or Multi-Use System for Low Bioburden Process

Components and Equipment

- Cleanable/ Sanitizable
- System Assembly · CIP required

System Integrity

Maintained post-CIP until clearance of product


Connections (post CIP)

- Functionally closure:
 - Flush, Sanitized or aseptic ⇒

Additions

Bioburden control/sterile prior to and during process

Maintenance of bacteriostatic state is critical









ng Conferences Services



CNC or Classified area

- Structural thinking for a classical problem...
- How to initially determine room classification for a given process step when I don't have enough information for a detailed risk assessment / analysis e.g. during concept design?

GMP based on Quality Risk	Management ICH9	
Not all potential hazards present the sar Risk = Impact x Probability x Detectabil QRM enables selection of controls that a conventional approaches or legacy proc	ity are proportionate to the risk identified, as opposed to a	dopting
Processinting CMD: the final	don sulo? for cloonsoom clossification?	
Prescriptive GMP: the "gol OPEN Process	den rule" for cleanroom classification? GRADE C	







Risk Assessment

- Evaluate the risk that a contamination from the surrounding air causes a bioburden contamination.
- Set the cleanroom classification based on that risk (cleanroom is a risk mitigation measure)
- Use a 'theoretical' method, i.e. assign scores to the risk factors and determine the cleanroom classification

```
Classification = f(risk left over)
= Impact x Probability x Detectability
Impact = f(Bioburden Limit, Growth Potential)
Probability = Mitigation = f(Closure)
```


Detectability = f(Detection)







The room classification model







Training, Conferences, Services,



Slide 17

Step 1 - Growth potential – 3 dimensions

$\frac{dx}{dt} = \exp\left(\mu_{max} \cdot T_{effect} \cdot N_{effect} \cdot t\right)$

(2)

Where:

- 1. µmax (in 1/h) is the maximum growth rate.
- 2. T effect is a factor between 0 and 100% to account on the temperature effect on the growth.
- 3. N effect is a factor between 0 and 100% to account on the growth promotion characteristics (i.e. nutrients) of the product/process solution.
- 4. t (in h) is the processing time where the contamination can grow. The processing time t can be seen as the time between when contamination occurs and when the next bioburden reduction step take place. For a buffer preparation it could be just a few hours whereas for an inoculum preparation can be for an extended period of multiple weeks.

Temperature	Optimum	Room temperature	Low temperature	
Range	30–36°C	20–25°C	2–8°C	
Rating	1.00	0.50	0.05	

Nutrients/Inhibition	Optimum	Limited	None
Range	Medium	C-source only	Water/Inhibition
Rating	1.00	0.50	0.10

Time	Short	Medium	Long
Range	<8h	8–24h	>24h
Rating	8	24	48








Pharmaceutical Quality

ning Conferences Service
















Pharmaceutical Quality Training. Conferences. Services.

Step 2 – Impact calculation

Function of growth potential and the process's Bioburden limit

Growth F	Potential					
Rating	Description					
Low	Process characteristic (e.g. temperature, time etc.) does not facilitate growth					
Medium	Growth is supported but partially limited by no perfect condition (e.g. limited nutrients, etc.)					
High	Perfect condition for growth (e.g. like in a bioreactor)					
Bioburde	en Limit					
Rating	Description					
Low	Controlled bioburden					
Medium	Low bioburden					
High	Aseptic or sterile like conditions					


Table 1. Growth Potential and Bioburden Limit definitions and rating







Step 2 - Impact evaluation







CONCEPT Supported by HEIDELBERG

Pharmaceutical Quality Training, Conferences, Services,



© ECA Academy – www.gmp-compliance.org

Probability

Probability = Mitigation = f(Closure)

Table 2. Probability definition and rating

Probabi	lity	
Rating	Description	
Low	Closed systems: maximum process/product protection	
High	Open systems: contamination is likely	

- The model is designed to be applied in situations such as early design phases e.g. concept design, and then you would define how the system is to be validated and operated closed via a further detailed assessment, as that level of detail would not be known at this stage.
- Basic assumptions:
 - Equipment is cleaned, sanitized and/or sterilized based on the intended use.







Detectability

Detectability				
Rating	Description			
Easy	In-line, i.e. higher degree of confidence that the contamination will be detected in real time			
Moderate	Off-line, i.e. contamination is detected but its assessment is limited (due to testing time lag)			
Difficult	Not detectable, i.e. contamination will probably not be detected			


- This is logical thinking for a truly risk-based approach.
- Unfortunately, following traditional GMP principles, use of detection is not accepted as a control
 measure as it is seen as not having a robust system/process. Nonetheless, a lower environmental
 classification is not synonymous with failure







Step 3 - Room Classification determination



ning Conferences Service

Risk evaluation examples

Application	Growth Promotion	Temperature	Time to Next Bioburden Reduction Step	Growth Potential	Bioburden Limit	Impact	Probability Closure	Detectability	Area Classification
Media preparation	High	RT ^b	<8 h	Medium	Controlled	Low	Open	Moderate	D
Inoculum	High	Optimum	>24 h	High	Sterile/aseptic	High	Open	Easy	С
Bioreactor	High	Optimum	>24 h	High	Sterile/aseptic	High	Closed	Easy	CNC
Cell factories	High	Optimum	>24 h	High	Sterile/aseptic	High	Open	Easy	С
Harvest	High	Low	<8 h	Low	Low bioburden	Low	Open	Easy	CNC
Harvest	High	RT	<8 h	Medium	Low bioburden	Medium	Open	Easy	D
Harvest	High	RT	<8 h	Medium	Low bioburden	Medium	Open	Moderate	С
Buffer preparation	Medium	RT	<8 h	Low	Controlled	Low	Open	Moderate	D
Buffer preparation	Medium	RT	<8 h	Low	Controlled	Low	Open	Moderate	D
Protein A	High	RT	<8 h	Medium	Low bioburden	Medium	Open	Easy	D
Chromatography	Medium	RT	<8 h	Low	Low bioburden	Low	Open	Easy	CNC
Chromatography	Medium	RT	<8 h	Low	Low bioburden	Low	Open	Moderate	D
Column packing	Low	RT	<8 h	Low	Low bioburden	Low	Open	Easy	CNC
Column packing	Low	RT	<8 h	Low	Low bioburden	Low	Open	Moderate	D
UF/DF ^r	Medium	RT	<8 h	Low	Low bioburden	Low	Open	Moderate	D
UF/DF	Medium	RT	<8 h	Low	Low bioburden	Low	Open	Difficult	С


^aClassifications: A = EU Grade A; C = EU Grade C; D = EU Grade D; and CNC = control not classified.

^bRT = room temperature.

^cUltra-Filtration/Dia-Filtration.









Pharmaceutical Quality Training, Conferences, Services.

Bioreactor

- Impact (High)
 - Bioburden limit => Axenic condition = aseptic or sterile
 - Growth potential => growth media, optimal temperature and long process time
- Probability (Closed)
 - Sterilised equipment and operated as closed process
- Detectability (EASY)
 - probability that a contamination from the environment is detected is high
 - CNC space is appropriate







Buffer preparation

- Impact (Low)
 - Bioburden limit => Controlled bioburden
 - Growth potential => medium growth potential, room temperature and short process time
- Probability (Open)
 - CIP'ed equipment and open operation during preparation
- Detectability (Moderate)
 - If probability that a contamination from the environment is detected is medium
 - Grade D space is appropriate, but if detection can be increased then CNC would be okay
 - With closed addition CNC would be appropriate







Chromatography


- Impact (Low)
 - Low Bioburden limit
 - Growth potential => medium in solvents, Room temperature and short process time
- Probability (Open due to preparation)
 - CIP or manual cleaning of equipment and operated as closed process
- Detectability (Moderate/Easy)
 - probability that a contamination from the environment is detected depend on process step
 - Grade D if Moderate detection otherwise CNC space is appropriate







Facility impact – How do we build it?



- Drives facility simplification
 - Classified space reduction
 - Simplify segregation
 - Promote flexibility
 - Enhancing product protection
 - Reduces risk

Supported by

• Reduce CAPEX and OPEX








Pharmaceutical Quality Training. Conferences. Services

Evaluating appropriate bioprocessing environments

- Closure Risk Assessment
- Assess Room classification
- Operational strategy
- Contamination/Cross contamination Risk Assessment
- Convenience/flexibility
- Segregation
- Single Use/Hybrid/Stainless steel










More segregated layout configuration









Pharmaceutical Quality Training. Conferences. Services



Pictures provided by CRB





Training, Conferences, Services,

Supported by



32





Pictures provided by CRB









Pharmaceutical Quality Training, Conferences, Services, 33

Grade D and CNC spaces in Drug Substance facility

- Grade D:
 - 100% Pharma finish



- CNC Space:
 - 61% Pharma finish
 - 39% Clean Industrial finish
- Communication & transfers between areas
- "Pleasing" the regulatory inspectors
- Aesthetics for clients, visitors and auditors











Pictures provided by CRB







Slide 35

Conclusion

With closed system it is possible to:

- Simplify & harmonise selection of room classification
- Meet regulatory requirements
- Justify ballroom facility
- Introduce lower room classification



Benefits

- Improving product quality and patient access to products
- Simplified design
- Reduction of capital and operational costs
- Reduced Cost of Quality
- Flexibility in facility operation







ing Conferences Service



Thank you for your attention

QUESTIONS?







Slide 37

Pharmaceutical Quality Training. Conferences. Services.

References and Relevant Literature

Nick Bevan, Tim Corbidge, David Estape, Lars Hovmand-Lyster, and Jorgen Magnus "Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations" PDA journal 2021

Chalk, S., Probst, S., Green, K., Moser, R., Urbanski, F., Zicaro, M., Smock, P., Pranzo, L., Dooley, L., McDuff, P., "New Challenges to the Cleanroom Paradigm for Multi-Product Facilities, May 2013.

Bio-Process Systems Alliance (BPSA), "Design, Control, and Monitoring of Single-Use Systems for Integrity Assurance," July 2017.

Probst, S. *et al*, "Data-Driven Equipment and Facility Design Case Study: Functional Closure of a Hybrid Connection System," BioPhorum Operations Group (BPOG) white paper, April 2018.

Blake, J., Estapé, D., Probst, S. et al, "BPOG Response to Annex 2," *PDA J Pharm Sci and Tech*, 2016, vol. 70, pp. 300-311.

Chalk, S., Taber, R., Probst, S., Gil, P., Palberg, T., Kennedy, M., Rogalewicz, J., Johnson, J., Green, K., "Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances." *BioPharm International*, August 2011.

Estapé, D. et al, "Proof of Closure: Life Cycle of Closed Systems," *Pharmaceutical Engineering*, September / October 2017.

ISPE baseline Pharmaceautical Engineering Guide for new and renovated facilities

"Biopharmaceautical Manufacturing Facilities Vol 6", second edition/November 2013





